ACT Genomics   Report issue

For profit Phase 2
Founded: Taipei City Taiwan (2014)

Organization Overview

First Clinical Trial
2020
NCT04377048
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

ACT Genomics

Active Ingredients

Drugs in Phase 2 Trials (5)

gemcitabine (gemzar) (1 trial)

gimeracil (1 trial)

nivolumab (opdivo) (1 trial)

oteracil (1 trial)

tegafur (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 5